塩酸サルポグレラートによる末梢動脈閉塞症に対する微小循環の改善

塩酸サルポグレラートが末梢循環に及ぼす影響を評価した。末梢動脈閉塞症13例を対象とし,非服用時の患肢足背部の経皮酸素分圧(tcPO2)値が50 mmHg未満12肢(A群)と50 mmHg以上(B群)14肢の2群に分類し,内服前後のtcPO2値を評価した。A群の内服前後と初回内服前と2週間後以降の投与前のtcPO2値で有意差を認めた。tcPO2値50 mmHg以下の末梢循環で投与効果が得られた。...

Full description

Saved in:
Bibliographic Details
Published in脈管学 Vol. 52; no. May; pp. 243 - 246
Main Authors 地引, 政利, 豊福, 崇浩, 井上, 芳徳, 工藤, 敏文
Format Journal Article
LanguageJapanese
Published 日本脈管学会 10.05.2012
Subjects
Online AccessGet full text
ISSN0387-1126
1880-8840
DOI10.7133/jca.52.243

Cover

Abstract 塩酸サルポグレラートが末梢循環に及ぼす影響を評価した。末梢動脈閉塞症13例を対象とし,非服用時の患肢足背部の経皮酸素分圧(tcPO2)値が50 mmHg未満12肢(A群)と50 mmHg以上(B群)14肢の2群に分類し,内服前後のtcPO2値を評価した。A群の内服前後と初回内服前と2週間後以降の投与前のtcPO2値で有意差を認めた。tcPO2値50 mmHg以下の末梢循環で投与効果が得られた。
AbstractList 塩酸サルポグレラートが末梢循環に及ぼす影響を評価した。末梢動脈閉塞症13例を対象とし,非服用時の患肢足背部の経皮酸素分圧(tcPO2)値が50 mmHg未満12肢(A群)と50 mmHg以上(B群)14肢の2群に分類し,内服前後のtcPO2値を評価した。A群の内服前後と初回内服前と2週間後以降の投与前のtcPO2値で有意差を認めた。tcPO2値50 mmHg以下の末梢循環で投与効果が得られた。
Author 工藤, 敏文
豊福, 崇浩
地引, 政利
井上, 芳徳
Author_xml – sequence: 1
  fullname: 地引, 政利
  organization: 東京医科歯科大学血管外科
– sequence: 1
  fullname: 豊福, 崇浩
  organization: 東京医科歯科大学血管外科
– sequence: 1
  fullname: 井上, 芳徳
  organization: 東京医科歯科大学血管外科
– sequence: 1
  fullname: 工藤, 敏文
  organization: 東京医科歯科大学血管外科
BookMark eNo9kE1LAkEAhocwyMxL_2NtvtadOUVIX2B0qWMss7tjuZjFrheP7hoaHoIoI6hAb2aYl6Ag_DPDaP6LNopOz-F5eQ_PMkhVz6oSgFUEcxYiZM13Rc7EOUzJAkgjxqDBGIUpkIaEWQZCOL8EsmFYdiCEnELCrTQ40r3B_OJdRW8qHqr4UUVjFb-oeKDiTxW3VWOooraKOtOH4bTf153br2Z73r3UvafZXSux-nWiGvfJQE9GenylJ8-z67FqjKY3H7rbXAGLJVEJZfaPGXC4tXlQ2DGK-9u7hY2i4WNIhOG4BEnLdRxmeZRKivMlTDnnbkl4DuaOSU1pMpdLiqBAHoceRQJ7xJQWw3nokAxY__31w5o4lvZ5UD4VQd0WQa3sVqSdlLFNbO-J-g-SQP_GPRGB7QvyDXO8gVE
ContentType Journal Article
Copyright 2012 日本脈管学会
Copyright_xml – notice: 2012 日本脈管学会
DOI 10.7133/jca.52.243
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 1880-8840
EndPage 246
ExternalDocumentID article_jca_52_May_52_243_article_char_ja
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
JSF
KQ8
RJT
ID FETCH-LOGICAL-j203a-bc31e7cbb87d44e426f24999cfadb29b545e58c9e410a1d90d41a2d35e78260b3
ISSN 0387-1126
IngestDate Wed Sep 03 06:30:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue May
Language Japanese
License https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j203a-bc31e7cbb87d44e426f24999cfadb29b545e58c9e410a1d90d41a2d35e78260b3
OpenAccessLink https://www.jstage.jst.go.jp/article/jca/52/May/52_243/_article/-char/ja
PageCount 4
ParticipantIDs jstage_primary_article_jca_52_May_52_243_article_char_ja
PublicationCentury 2000
PublicationDate 2012/05/10
PublicationDateYYYYMMDD 2012-05-10
PublicationDate_xml – month: 05
  year: 2012
  text: 2012/05/10
  day: 10
PublicationDecade 2010
PublicationTitle 脈管学
PublicationTitleAlternate 脈管学
PublicationYear 2012
Publisher 日本脈管学会
Publisher_xml – name: 日本脈管学会
References 6)Hara H, Kitajima A, Shimada H, et al: Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost 1991; 66: 484-488
20)Greenwald RA: The "doctor's letter"-what is our obligation? N Engl J Med 1991; 324: 64
3)Wright L, Homans DC, Laxson DD, et al: Effect of serotonin and thromboxane A2 on blood flow through moderately well developed coronary collateral vessels. J Am Coll Cardiol 1992; 19: 687-693
15)Castronuovo JJ, Pabst TS, Flanigan DP, et al: Noninvasive determination of skin perfusion pressure using a laser Doppler. J Cardiovasc Surg (Torino) 1987; 28: 253-257
1)Norgren L, Hiatt WR, Dormandy JA, et al: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-S75
19)Doggrell SA: Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs 2004; 13: 865-874
22)Matsuo H, Shigematsu H: Effects of the 5-HT2A antagonist sarpogrelate hydrochloride on walking ability in patients with intermittent claudication as measured using the walking impairment questionnaire. Ann Vasc Dis 2008; 1: 102-110
11)Lalka SG, Malone JM, Anderson GG, et al: Transcutaneous oxygen and carbon dioxide pressure monitoring to determine severity of limb ischemia and to predict surgical outcome. J Vasc Surg 1988; 7: 507-514
13)Mathieu D, Mani R: A review of the clinical significance of tissue hypoxia measurements in lower extremity wound management. Int J Low Extrem Wounds 2007; 6: 273-283
18)Cina C, Katsamouris A, Megerman J, et al: Utility of transcutaneous oxygen tension measurements in peripheral arterial occlusive disease. J Vasc Surg 1984; 1: 362-371
23)磯貝行秀,横瀬琢男,池本 卓,他:塩酸サルポグレラート(MCI-9042)の第I相臨床試験─単回および連続経口投与試験─.臨床医薬 1991; 7: 1177-1192
5)Nakamura K, Kariyazono H, Moriyama Y, et al: Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin. Blood Coagul Fibrinolysis 1999; 10: 513-519
9)Yamakawa J, Takahashi T, Saegusa S, et al: Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. J Int Med Res 2004; 32: 166-169
10)Ballard JL, Eke CC, Bunt TJ, et al: A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. J Vasc Surg 1995; 22: 485-490; discussion 490-492
7)Yamashita T, Kitamori K, Hashimoto M, et al: Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models. Haemostasis 2000; 30: 321-332
8)Norgren L, Jawien A, Mátyás L, et al: Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. Vasc Med 2006; 11: 75-83
17)Bacharach JM, Rooke TW, Osmundson PJ, et al: Predictive value of transcutaneous oxygen pressure and amputation success by use of supine and elevation measurements. J Vasc Surg 1992; 15: 558-563
21)Miyazaki M, Higashi Y, Goto C, et al: Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 2007; 49: 221-227
4)Hara H, Osakabe M, Kitajima A, et al: MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-420
14)Ubbink DT, Jacobs MJ, Tangelder GJ, et al: The usefulness of capillary microscopy, transcutaneous oximetry and laser Doppler fluxmetry in the assessment of the severity of lower limb ischaemia. Int J Microcirc Clin Exp 1994; 14: 34-44
2)Barradas MA, Gill DS, Fonseca VA, et al: Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404
16)Beran AV, Tolle CD, Huxtable RF: Cutaneous blood flow and its relationship to transcutaneous O2/CO2 measurements. Crit Care Med 1981; 9: 736-741
12)Ubbink DT, Tulevski II, den Hartog D, et al: The value of non-invasive techniques for the assessment of critical limb ischaemia. Eur J Vasc Endovasc Surg 1997; 13: 296-300
References_xml – reference: 3)Wright L, Homans DC, Laxson DD, et al: Effect of serotonin and thromboxane A2 on blood flow through moderately well developed coronary collateral vessels. J Am Coll Cardiol 1992; 19: 687-693
– reference: 21)Miyazaki M, Higashi Y, Goto C, et al: Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 2007; 49: 221-227
– reference: 13)Mathieu D, Mani R: A review of the clinical significance of tissue hypoxia measurements in lower extremity wound management. Int J Low Extrem Wounds 2007; 6: 273-283
– reference: 5)Nakamura K, Kariyazono H, Moriyama Y, et al: Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin. Blood Coagul Fibrinolysis 1999; 10: 513-519
– reference: 16)Beran AV, Tolle CD, Huxtable RF: Cutaneous blood flow and its relationship to transcutaneous O2/CO2 measurements. Crit Care Med 1981; 9: 736-741
– reference: 23)磯貝行秀,横瀬琢男,池本 卓,他:塩酸サルポグレラート(MCI-9042)の第I相臨床試験─単回および連続経口投与試験─.臨床医薬 1991; 7: 1177-1192
– reference: 8)Norgren L, Jawien A, Mátyás L, et al: Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. Vasc Med 2006; 11: 75-83
– reference: 18)Cina C, Katsamouris A, Megerman J, et al: Utility of transcutaneous oxygen tension measurements in peripheral arterial occlusive disease. J Vasc Surg 1984; 1: 362-371
– reference: 14)Ubbink DT, Jacobs MJ, Tangelder GJ, et al: The usefulness of capillary microscopy, transcutaneous oximetry and laser Doppler fluxmetry in the assessment of the severity of lower limb ischaemia. Int J Microcirc Clin Exp 1994; 14: 34-44
– reference: 10)Ballard JL, Eke CC, Bunt TJ, et al: A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. J Vasc Surg 1995; 22: 485-490; discussion 490-492
– reference: 22)Matsuo H, Shigematsu H: Effects of the 5-HT2A antagonist sarpogrelate hydrochloride on walking ability in patients with intermittent claudication as measured using the walking impairment questionnaire. Ann Vasc Dis 2008; 1: 102-110
– reference: 6)Hara H, Kitajima A, Shimada H, et al: Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost 1991; 66: 484-488
– reference: 15)Castronuovo JJ, Pabst TS, Flanigan DP, et al: Noninvasive determination of skin perfusion pressure using a laser Doppler. J Cardiovasc Surg (Torino) 1987; 28: 253-257
– reference: 2)Barradas MA, Gill DS, Fonseca VA, et al: Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404
– reference: 1)Norgren L, Hiatt WR, Dormandy JA, et al: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-S75
– reference: 19)Doggrell SA: Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs 2004; 13: 865-874
– reference: 9)Yamakawa J, Takahashi T, Saegusa S, et al: Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. J Int Med Res 2004; 32: 166-169
– reference: 20)Greenwald RA: The "doctor's letter"-what is our obligation? N Engl J Med 1991; 324: 64
– reference: 11)Lalka SG, Malone JM, Anderson GG, et al: Transcutaneous oxygen and carbon dioxide pressure monitoring to determine severity of limb ischemia and to predict surgical outcome. J Vasc Surg 1988; 7: 507-514
– reference: 4)Hara H, Osakabe M, Kitajima A, et al: MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-420
– reference: 17)Bacharach JM, Rooke TW, Osmundson PJ, et al: Predictive value of transcutaneous oxygen pressure and amputation success by use of supine and elevation measurements. J Vasc Surg 1992; 15: 558-563
– reference: 7)Yamashita T, Kitamori K, Hashimoto M, et al: Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models. Haemostasis 2000; 30: 321-332
– reference: 12)Ubbink DT, Tulevski II, den Hartog D, et al: The value of non-invasive techniques for the assessment of critical limb ischaemia. Eur J Vasc Endovasc Surg 1997; 13: 296-300
SSID ssib000940397
ssib005879700
ssib051641554
ssj0002920462
ssib002227066
ssib058493671
ssib050995460
Score 1.902105
Snippet 塩酸サルポグレラートが末梢循環に及ぼす影響を評価した。末梢動脈閉塞症13例を対象とし,非服用時の患肢足背部の経皮酸素分圧(tcPO2)値が50 mmHg未満12肢(A群)と50 mmHg以...
SourceID jstage
SourceType Publisher
StartPage 243
SubjectTerms 5-HT2A receptor blocker
collateral
key words:5-hydroxytryptamine (5-HT)
microcirculation
vascular spasm
Title 塩酸サルポグレラートによる末梢動脈閉塞症に対する微小循環の改善
URI https://www.jstage.jst.go.jp/article/jca/52/May/52_243/_article/-char/ja
Volume 52
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 脈管学, 2012/05/10, Vol.52(May), pp.243-246
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1880-8840
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002920462
  issn: 0387-1126
  databaseCode: KQ8
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1880-8840
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib051641554
  issn: 0387-1126
  databaseCode: M~E
  dateStart: 19610101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1Na9RANNR68SKKit_04BxTk8lMZuaYbFOKUE8t9CIhM0kPe6gi7aUHobsVKz0IohVBhfZWK7UXQUH2twghrf0Xvpkku6OI1MKSfbx58-Z9JPvezM68OM4dxZlSQhE39AhxScYCV-ZEuZDpQnAoSF4s6vPOs_fDmXlyb4EujJ35Ye1aWlmWk2r1r-dKTuNVwIFf9SnZ__DskCkgAAb_whU8DNcT-RglFEU-igRKBOIUxRwlAeIYxdQAAYriBhBTbZPXNnVaQDRA3GJ4zcdvu-MWAwBgQiQ6pilEEdYfEAPwAgbliBNDLJAIEReNhCJBCUOCIc4sztA0jeKkwQhhDUE1PkoM4CE-3WIiw2eohW9oQB6CYjOWHpTYCbclEtPEIIwedwpFwyVJ069jWFJtA9AD7ruWrRkaukdiRM9R7CNuZIlCLZ2hh87EKBhq-9v0wCYy5iHaRdDR0BsoDhrV4sCWJwbOxpxgs4gM5aHGFKFRk9kLNnrni671OnzEDFXNpHZX5x-WMIKB4pEVFnQ1ZH3wq47gddiCX2GX87rwVRvXKLae39lmS1YTpurSWE3Gg-tF4D-DqV6-0MFUZZMUTw67_FacvLn1UyBKKU5hFP0FtGnbog8Ppl2YwZzFLAz1O0ZmnyRWgk-8QNgLCpjZ7xegnAmrgCRkt4KS0YSewmTfToghmxZBW7BR52L6XWwkrP9KbMxW1yjWyt0dqQb5ZxdmY-1OTpNczl1wzjezwomo1uaiM9bNLjkPqu3d46dfy96Xsr9X9t-XvYOy_6ns75b972V_o1zbK3sbZW_z8N3e4c5Otfn65_rG8dbzavvD0Ztn0Fp9HpRrb4GgGuxXBy-qwcejlwfl2v7hq2_V1vplZ346mevMuM3bUNwu9oLMlSrwC6ak5CwnpIDMehHr5Qq1mOUSCwlToYJyJQrie5mfCy8nfobzgBYwCQg9GVxxxpceLhVXnYkccnolA8GFX0AMl9Jj2Ct8X_lEekTQaw6vrZE-qkvepCf28_XTd73hnBs9Ljed8eXHK8UtyPiX5W1z0_wC68jV8g
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%A1%A9%E9%85%B8%E3%82%B5%E3%83%AB%E3%83%9D%E3%82%B0%E3%83%AC%E3%83%A9%E3%83%BC%E3%83%88%E3%81%AB%E3%82%88%E3%82%8B%E6%9C%AB%E6%A2%A2%E5%8B%95%E8%84%88%E9%96%89%E5%A1%9E%E7%97%87%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E5%BE%AE%E5%B0%8F%E5%BE%AA%E7%92%B0%E3%81%AE%E6%94%B9%E5%96%84&rft.jtitle=%E8%84%88%E7%AE%A1%E5%AD%A6&rft.au=%E5%9C%B0%E5%BC%95%2C+%E6%94%BF%E5%88%A9&rft.au=%E8%B1%8A%E7%A6%8F%2C+%E5%B4%87%E6%B5%A9&rft.au=%E4%BA%95%E4%B8%8A%2C+%E8%8A%B3%E5%BE%B3&rft.au=%E5%B7%A5%E8%97%A4%2C+%E6%95%8F%E6%96%87&rft.date=2012-05-10&rft.pub=%E6%97%A5%E6%9C%AC%E8%84%88%E7%AE%A1%E5%AD%A6%E4%BC%9A&rft.issn=0387-1126&rft.eissn=1880-8840&rft.volume=52&rft.issue=May&rft.spage=243&rft.epage=246&rft_id=info:doi/10.7133%2Fjca.52.243&rft.externalDocID=article_jca_52_May_52_243_article_char_ja
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0387-1126&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0387-1126&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0387-1126&client=summon